NIH R33 funding opportunities: Exploratory/Developmental Grant Phase II
36 NIH notices for R33 (Exploratory/Developmental Grant Phase II) are open and 3 forecast. The second phase of a phased award, usually following an R61 or R21...
- Open notices36
- Forecast3
- Projects funded under them7,528
Open NIH R33 notices
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Open Closes November 10, 2026 (3 days left) - NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Open - NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
Open - Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
Open - HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
Open - Translational Neural Devices (R61/R33 - Clinical Trial Optional)
Open - NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
Open - NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Open - Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Open - Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
Open - Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
Open - Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Open - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
Open - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
Open - Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
Open - Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
Open - Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)
Open - Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
Open - Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
Open - Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Open - Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)
Open - Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Open - Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
Open - Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
Open - Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
Open - Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
Open - Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
Open - Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)
Open - INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
Open - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Open - Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Open - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Open - HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
Open - Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
Open - Assessing the Feasibility of Incorporating Mechanisms in Multi-site Clinical Trials of Mind and Body Interventions on Whole Person Health Restoration (R33 Clinical Trial Required)
Open - NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Open
Forecast R33 notices
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Forecast - Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)
Forecast - HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)
Forecast
Institutes that fund R33 projects under these notices
| Institute or center | Projects |
|---|---|
| National Cancer Institute (NCI) | 1,044 |
| National Heart Lung and Blood Institute (NHLBI) | 866 |
| National Institute on Aging (NIA) | 710 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 666 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 600 |
| National Institute of General Medical Sciences (NIGMS) | 590 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 461 |
| National Institute on Drug Abuse (NIDA) | 448 |
| National Institute of Mental Health (NIMH) | 384 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 343 |
Closed R33 notices
- PAR-27-045: HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
- PAR-25-242: Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)
- PAR-25-028: Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
- PAR-25-223: Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R61/R33 Clinical Trial Required)
- RFA-CA-25-004: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- RFA-CA-25-002: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- PAR-25-218: Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)
- PAR-25-219: Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)
- RFA-HD-26-001: Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
- RFA-DA-25-063: Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
- PAR-24-267: Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
- PAR-23-157: Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
- RFA-DA-24-066: HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)
- RFA-DA-24-033: Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
- RFA-DA-24-034: Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
- RFA-AI-24-080: Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)
- RFA-DA-25-077: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
- RFA-DA-25-078: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
- PAR-25-335: NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
- PAR-25-363: NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
- RFA-AI-24-076: Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)
- PAR-22-233: Time-Sensitive Opportunities for Health Research (R61/R33 Clinical Trial Not Allowed)
- RFA-DA-26-024: Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R33 Clinical Trial Optional)
- PA-23-189: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
- RFA-AI-24-068: New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)
- RFA-AI-24-065: Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)
- RFA-MH-26-100: BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional)
- PAR-24-062: Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
- PAR-22-189: Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
- PAR-24-173: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
- PAR-23-205: NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
- PAR-23-200: NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
- PAR-24-172: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
- RFA-DA-23-053: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
- RFA-DA-23-054: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
- PAR-23-318: Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)
- RFA-NS-24-035: Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
- PAR-24-116: NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- PAR-24-124: NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- RFA-DA-25-014: Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
- PAR-24-068: Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- RFA-HL-23-010: Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
- RFA-HL-23-011: Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
- RFA-HL-23-014: Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
- RFA-HL-23-012: Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
- RFA-HL-23-013: Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
- RFA-DA-23-028: NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
- RFA-DA-23-029: NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
- RFA-DA-23-008: Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)
- RFA-NS-25-011: Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
- PAR-23-053: Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)
- PAR-23-054: Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)
- RFA-AG-25-019: The Impact of Stressors on the Biological Mechanisms of Aging and Other Aging-Associated Outcomes in Experimental Model Systems (R61/R33 Clinical Trial Not allowed)
- PAR-25-058: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
- PAR-24-238: Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
- PAR-24-239: Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
- PAR-24-151: Translational Neural Devices (R61/R33 - Clinical Trial Optional)
- PAR-22-089: Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
- PAR-21-123: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
- PAR-21-124: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
- PAR-21-122: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
- PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
- PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
- PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
- PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
- RFA-AG-25-024: Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
- RFA-CA-24-011: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- RFA-CA-24-009: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- RFA-NS-25-012: HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- PAR-21-250: Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)
- RFA-EY-24-003: NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional)
- PAR-23-041: Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
- RFA-OD-22-010: Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)
- PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- RFA-HD-25-008: Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)
- PAR-23-089: Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61/R33 Clinical Trial Not Allowed)
- RFA-AI-23-061: Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)
- RFA-MH-23-335: BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional)
- PAR-21-308: Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 Clinical Trial Required)
- RFA-DA-24-030: Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed)
- RFA-AG-24-046: Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)
- RFA-AI-23-055: Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed)
- RFA-DA-24-036: Rural Community-Centered Drug Misuse Prevention and Harm Reduction Research: Addressing Implementation, Dissemination, and Equity Challenges across the Continuum of Care (R61/R33 Clinical Trial Only)
- PAR-21-118: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)
- PAR-21-119: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)
- RFA-MH-24-100: Precision HIV Health: Integrating Data and Implementation Science to Accelerate HIV Prevention and Treatment (R21/R33 Clinical Trial Not Allowed)
- RFA-NS-24-026: Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional)
- RFA-DA-24-024: Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required)
- RFA-DA-24-029: Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required)
- RFA-AG-24-050: Health Equity and the Cost of Novel Treatments for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)
- PAR-23-154: Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
- RFA-AG-24-048: Primary Care-Based Screening Tool and Intervention Development for the Detection and Prevention of Abuse and Neglect in Older and Vulnerable Adults With, or at Risk for, Mild Cognitive Impairment and AD/ADRD (R61/R33 Clinical Trial Required)
- RFA-AT-24-003: HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required)
- RFA-AG-24-020: Networking/Infrastructure Project for Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging Related Outcomes, and Prospects for Translation (R61/R33 Clinical Trial Not Allowed)
- RFA-AG-24-018: Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed)
- PAR-23-195: Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)
- RFA-NS-24-010: Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
- RFA-CA-23-003: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- RFA-CA-23-005: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- RFA-DA-24-015: Ending the HIV Epidemic: Focus on Justice Populations with SUD (R61/R33 Clinical Trial Required)
Questions people ask
What is an NIH R33?
R33 is NIH's activity code for the Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Each notice sets its own budget limit, project length and due dates.
How many NIH R33 funding opportunities are open?
36 notices are open on Grants.gov, and 3 more are forecast, as of the latest data.